| Literature DB >> 30275919 |
Izumi Makino1, Young-Chang Arai1,2, Shuichi Aono1, Masayuki Inoue1,2, Hiroki Sakurai3, Yusuke Ohmichi1, Kazuhiro Shimo1,2, Makoto Nishihara1, Jun Sato1, Noboru Hatakeyama1, Takako Matsubara1,3, Tatsunori Ikemoto1,2, Takahiro Ushida1,2.
Abstract
Objective: To retrospectively analyze the effects of our original combination therapy treatment on patients with nonodontogenic persistent dentoalveolar pain.Entities:
Mesh:
Year: 2018 PMID: 30275919 PMCID: PMC6157115 DOI: 10.1155/2018/5042067
Source DB: PubMed Journal: Pain Res Manag ISSN: 1203-6765 Impact factor: 3.037
Figure 1Jaw exercise. (a) Protusion-retrusion jaw movements while biting on a cotton roll with the front teeth. (b) Right jaw movement while biting on a cotton roll with the right canine. (c) Left jaw movement while biting on a cotton roll with the left canine.
Figure 2Mouth exercise and relaxation. (a) Take a breath with the mouth wide open. (b) Roll the lips back inside the mouth. (c) Close the mouth until the lips touch. (d) Relax the masticatory muscles, tongue, and jaw without letting the teeth touch.
Characteristics and treatment used in 21 patients.
| Patientnumber | Sex | Age (years) | Duration (months) | Pain location | History of present illness | Phamacological treatment | OPA | HADS | PCS | |
|---|---|---|---|---|---|---|---|---|---|---|
| (anxiety) | (depression) | |||||||||
| 1 | F | 70 | 30 | 34 | rct | NSAIDs | c, t | 14 | 15 | — |
| 2 | F | 37 | 4 | 14.15 | none | Tizanidine hydrochloride NSAIDs | c | 6 | 5 | 36 |
| 3 | F | 58 | 7 | (21) area | ext and cur | NSAIDs | t | 7 | 5 | 23 |
| 4 | F | 27 | 7 | 16.26.36.46 | rct | Mirtazapine-lorazepam | c, t | 16 | 16 | 40 |
| 5 | F | 59 | 48 | 36.37 | none | Flunitrazepam-etizolam | c, t | 18 | 18 | 51 |
| 6 | F | 71 | 6 | 36.37 | cr | Etizolam | c, t | 9 | 3 | 40 |
| 7 | F | 39 | 48 | 26.27 | none | Lorazepam | c | 10 | 6 | 32 |
| 8 | F | 37 | 36 | (26) area | ext and cur | Clonazepam-gabapentin carbamazepine-pregabalin | c, t | 9 | 8 | 19 |
| 9 | F | 74 | 36 | (46) area | rct and ext | NSAIDs | — | 12 | 10 | 47 |
| 10 | F | 75 | 240 | (24.25.26) area | ext | NSAIDs | c, t | 8 | 4 | 42 |
| 11 | F | 82 | 24 | 11.14.21 | none | NSAIDs | c | 3 | 13 | 31 |
| 12 | M | 58 | 24 | 6.17.26.27.36.37.46.47 | none | Pregabalin-brotizolam | j | 13 | 14 | 37 |
| 13 | M | 78 | 24 | 37 | br | NSAIDs | t | 8 | 8 | 38 |
| 14 | F | 89 | 3 | 16 (44.45.46.47) area | ext and cur | Mirtazapine | t | 15 | 18 | 50 |
| 15 | F | 72 | 3 | 11.12.13 (16) area | none | Pregabalin-carbamazepine NSAIDs | c, t | 12 | 16 | 45 |
| 16 | F | 44 | 36 | 25 (26) area | ext | Drugs for bipolar disorder | c | 18 | 18 | — |
| 17 | F | 39 | 30 | 26 | rct and ext | Drugs for schizophrenia | c, t | 7 | 11 | 22 |
| 18 | F | 46 | 36 | 13.38 | none | Drugs for schizophrenia | c | 11 | 18 | 44 |
| 19 | F | 69 | 36 | (37.38) area | ext | Amitriptyline-NSAIDs-pregabalin | — | 3 | 2 | 15 |
| 20 | F | 24 | 18 | All teeth | none | Drugs for obsessive-compulsive disorder | — | 13 | 9 | 46 |
| 21 | F | 21 | 96 | 26 | None → pulpectomy | Amitriptyline | c | 14 | 9 | 40 |
| Mean | 55.7 | 37.7 | 10.8 | 10.8 | 36.7 | |||||
Tooth number is shown by two-digit notation (FDI). (Number) area is in situ after extraction of tooth. History of present illness: none = nontreatment; ext = extraction of tooth; rct = root canal treatment; cur = curettage of alveolar bone. cr = crown, br = bridge, OPA: c = diurnal tooth clenching; t = touching tooth by tongue; j = jaw moving; HADS = Hospital Anxiety and Depression Scale to determine the levels of anxiety and depression. PCS = Pain Catastrophizing Scale to determine the levels of physical and emotional distress associated with their pain.
The pain intensity in each visiting time at pain center.
| Patient number | Before | 1 month | 3 months | End |
|---|---|---|---|---|
| 1 | 8 | 5 | 5 | 0 |
| 2 | 8 | 2 | 2 | 0 |
| 3 | 5 | 3 | 0 | 0 |
| 4 | 8 | 10 | 0 | 0 |
| 5 | 8 | 8 | 4 | 1 |
| 6 | 5 | 2 | 1 | 1 |
| 7 | 7 | 0 | 0 | 0 |
| 8 | 10 | 10 | 10 | 10 |
| 9 | 9 | 9 | 5 | 5 |
| 10 | 8 | 0 | 6 | 5 |
| 11 | 8 | 0 | 0 | 0 |
| 12 | 8 | 1 | 0 | 0 |
| 13 | 8 | 8 | 2 | 0 |
| 14 | 10 | 0 | 0 | 0 |
| 15 | 10 | 0 | 0 | 0 |
| Mean | 8 | 4 | 2 | 1 |
| Median | 8 | 2 | 1 | 0 |
|
| 0.0051 | 0.007 | 0.007 |
The NRSs of the baseline ranged from 5 to 10 (median, 8). The NRS ranged from 0 to 10 (median, 0) at one month after treatment. The NRS ranged from 0 to 10 (median, 0) at three month after treatment. The NRS ranged from 0 to 10 (median, 0) at the end of treatment. P value: the data were analyzed by Wilcoxon signed-rank test between the initial pain and the pain intensity at one month later, three month later, and end of treatment.
Figure 3The pain intensity in each visiting time at pain center. Horizontal bar represents medians, boxes represent the 25th and 75th percentile ranges, and T bars represent the 5th and 95th percentile ranges. Difference between before and after treatment (P < 0.01) (Wilcoxon test).
The condition in the follow-up.
| Patient number | NRS | Medicine |
|---|---|---|
| 1 | 3∼6 | None |
| 2 | 1∼2 | None |
| 3 | 0 | None |
| 4 | 2∼3 | None |
| 5 | 0 | None |
| 6 | 3∼5 | Sometime |
| 7 | 0 | None |
| 8 | 10 | Usual |
| 9 | — | — |
| 10 | 0∼1 | None |
| 11 | 3∼8 | None |
| 12 | 3∼5 | None |
| 13 | 0∼5 | None |
| 14 | — | — |
| 15 | — | — |
The NRS ranges from 0 to 10, and ten patients took no medication, one patient occasionally took medication in the follow-up.